Develops diagnostics for kidney diseases, focusing on improving kidney health management.
Renalytix Plc specializes in developing cutting-edge, artificial intelligence-enabled in vitro diagnostic solutions tailored for kidney diseases. Central to its portfolio is KidneyIntelX, an innovative diagnostic platform that integrates an AI-driven algorithm. This algorithm harnesses validated blood-based biomarkers, inherited genetics, and personalized patient data sourced from electronic health records to generate a unique risk score for each patient. Renalytix Plc's products play pivotal roles in kidney disease diagnosis, prognosis, clinical management, patient stratification for drug trials, and the discovery of new drug targets.
The company has established strategic partnerships to advance its mission. Renalytix Plc holds a license agreement with Mount Sinai Health System for developing and commercializing AI-based kidney disease diagnostics. Additionally, partnerships with Joslin Diabetes Center, Inc. and Kantaro Biosciences LLC further enhance its capabilities in biomarker-based diagnostics and laboratory tests for SARS-CoV-2 antibodies, respectively. Renalytix Plc collaborates closely with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement advanced clinical care models aimed at enhancing kidney health outcomes and reducing disease progression and kidney failure in high-risk populations.
Founded in 2018 and headquartered in New York, New York, Renalytix Plc was formerly known as Renalytix AI plc before rebranding in June 2021. The company continues to innovate at the intersection of AI and healthcare, striving to make significant advancements in the early detection and management of kidney diseases worldwide.